Loading clinical trials...

RECRUITINGNA

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

NCT05240352•The University of Texas Health Science Center, Houston

Summary

The purpose of this study is to investigate whether transcranial direct-current stimulation (tDCS) will engage reward-related brain circuitry, more specifically the uncinate fasciculus (UF) tract, which connects the orbitofrontal cortex (OFC) and nucleus accumbens (NAcc) regions. Also to evaluate whether the changes in the fractional anisotropy (FA) of the UF tract are associated with changes of clinical symptoms of anhedonia and finally to investigate the moderation role of simulated electric fields (EFs) in an association between FA of the UF and symptoms of anhedonia.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•diagnosis of Bipolar Disorder and clinically significant anhedonia
•mild symptoms of depression

Exclusion Criteria

•substance abuse/dependence and any use of drugs (except alcohol or nicotine) in the previous month of the baseline assessment
•participants with personality disorder that would interfere with study participation according to clinical judgment
•previous neurological conditions (epilepsy, traumatic brain injury, stroke, etc)
•any severe, life-threatening non-psychiatric medical condition
•specific contraindications for tDCS (metallic plates in the head)
•Participants identified as acutely suicidal or severely agitated

Locations (1)

The University of Texas Health Science Center at Houston

Houston, Texas, United States

Key Dates

Start Date

October 6, 2022

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

February 18, 2026

Enrollment

ESTIMATED participants

Conditions

Anhedonia

Interventions

active tDCS

DEVICE

sham tDCS

DEVICE

Contacts

Jair C Soares, MD,PhD

CONTACT

(713) 486-6663 UTMoodDisorders@uth.tmc.edu

Alexandre P Diaz, MD,PhD

CONTACT

(713) 486-6663 UTMoodDisorders@uth.tmc.edu

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

NCT07146503

Depression and Quality of LifeTreatment Resistant Depression (TRD)+6 more

View study

RECRUITINGPHASE2

Inflammation and Depression in People With HIV

NCT05849038

HIVDepression+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

Inclusion Criteria

Exclusion Criteria

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

Inflammation and Depression in People With HIV

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Psilocybin for Treatment-Resistant Depression

Promoting Positive Emotional Functioning in Police and Military Populations

tVNS and Approach-Avoidance Behavior in Anhedonia and Anxiety